Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma

Science Signaling

Volumn 7, Issue 338, 2014, Pages

  Kusne, Yael ^a,b   Carrera Silva, Eugenio A ^c   Perry, Anthony S ^d   Rushing, Elisabeth J ^e,k   Mandell, Edward K ^c   Dietrich, Justin D ^f,l   Errasti, Andrea E ^c   Gibbs, Daniel ^g   Berens, Michael E ^h   Loftus, Joseph C ⁱ   Hulme, Christopher ^f   Yang, Weiwei ^j   Lu, Zhimin ^j   Aldape, Kenneth ^j   Sanai, Nader ^a,b   Rothlin, Carla V ^c   Ghosh, Sourav ^a,b,c,h  

^a ARIZONA STATE UNIVERSITY   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Banner MD Anderson Cancer Center   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l ABBVIE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ATYPICAL PROTEIN KINASE C; CHLORDANE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GELATINASE B; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHALLOIDIN; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PZ 09; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; WORTMANNIN; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR; PKC-3 PROTEIN; QUINAZOLINE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BONE MARROW CELL; BRAIN TISSUE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CAUDATE NUCLEUS; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; CEREBELLUM; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE CLUSTER; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA CELL; GRAY MATTER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MONOCYTE; MOUSE; NERVE CELL; NOD SCID MOUSE; NONHUMAN; OLIGODENDROGLIA; PARACRINE SIGNALING; PLACENTA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TESTIS; THERAPY EFFECT; TISSUE MICROARRAY; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT; WHITE MATTER; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; KAPLAN MEIER METHOD; METABOLISM; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; ERLOTINIB HYDROCHLORIDE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MICE; NF-KAPPA B; PARACRINE COMMUNICATION; PROTEIN KINASE C; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906094991     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005196     Document Type: Article

References (78)

1. F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, L. Chin, R. A. DePinho, W. K. Cavenee, Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710 (2007).
2. SEER, http://seer.cancer.gov/.
3. CBTRUS, http://www.cbtrus.org/.
4. I. K. Mellinghoff, N. Schultz, P. S. Mischel, T. F. Cloughesy, Will kinase inhibitors make it as glioblastoma drugs? Curr. Top. Microbiol. Immunol. 355, 135-169 (2012).
5. M. R. Gilbert, Recurrent glioblastoma: A fresh look at current therapies and emerging novel approaches. Semin. Oncol. 38 (Suppl. 4), S21-S33 (2011).
6. S. Kesari, Understanding glioblastoma tumor biology: The potential to improve current diagnosis and treatments. Semin. Oncol. 38 (Suppl. 4), S2-S10 (2011).
7. I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H. Huang, D. J. Chute, B. L. Riggs, S. Horvath, L. M. Liau, W. K. Cavenee, P. N. Rao, R. Beroukhim, T. C. Peck, J. C. Lee, W. R. Sellers, D. Stokoe, M. Prados, T. F. Cloughesy, C. L. Sawyers, P. S. Mischel, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
8. I. K. Mellinghoff, T. F. Cloughesy, P. S. Mischel, PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 13, 378-381 (2007).
9. E. Berra, M. T. Diaz-Meco, I. Dominguez, M. M. Municio, L. Sanz, J. Lozano, R. S. Chapkin, J. Moscat, Protein kinase C ζ isoform is critical for mitogenic signal transduction. Cell 74, 555-563 (1993).
10. V. Aranda, T. Haire, M. E. Nolan, J. P. Calarco, A. Z. Rosenberg, J. P. Fawcett, T. Pawson, S. K. Muthuswamy, Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat. Cell Biol. 8, 1235-1245 (2006).
11. K. Akimoto, R. Takahashi, S. Moriya, N. Nishioka, J. Takayanagi, K. Kimura, Y. Fukui, S. Osada, K. Mizuno, S. Hirai, A. Kazlauskas, S. Ohno, EGF or PDGF receptors activate atypical PKCl through phosphatidylinositol 3-kinase. EMBO J. 15, 788-798 (1996).
12. S. Ghosh, T. Marquardt, J. P. Thaler, N. Carter, S. E. Andrews, S. L. Pfaff, T. Hunter, Instructive role of aPKCλ subcellular localization in the assembly of adherens junctions in neural progenitors. Proc. Natl. Acad. Sci. U.S.A. 105, 335-340 (2008).
13. J. I. Trujillo, J. R. Kiefer, W. Huang, A. Thorarensen, L. Xing, N. L. Caspers, J. E. Day, K. J. Mathis, K. K. Kretzmer, B. A. Reitz, R. A. Weinberg, R. A. Stegeman, A. Wrightstone, L. Christine, R. Compton, X. Li, 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: Design and synthesis of a potent and isoform selective PKC-ζ inhibitor. Bioorg. Med. Chem. Lett. 19, 908-911 (2009).
14. A. Pandita, K. D. Aldape, G. Zadeh, A. Guha, C. D. James, Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39, 29-36 (2004).
15. C. Giannini, J. N. Sarkaria, A. Saito, J. H. Uhm, E. Galanis, B. L. Carlson, M. A. Schroeder, C. D. James, Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 7, 164-176 (2005).
16. J. N. Sarkaria, L. Yang, P. T. Grogan, G. J. Kitange, B. L. Carlson, M. A. Schroeder, E. Galanis, C. Giannini, W. Wu, E. B. Dinca, C. D. James, Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 6, 1167-1174 (2007).
17. Q. W. Fan, C. K. Cheng, W. C. Gustafson, E. Charron, P. Zipper, R. A. Wong, J. Chen, J. Lau, C. Knobbe-Thomsen, M. Weller, N. Jura, G. Reifenberger, K. M. Shokat, W. A. Weiss, EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 24, 438-449 (2013).
18. E. E. Cohen, M. W. Lingen, B. Zhu, H. Zhu, M. W. Straza, C. Pierce, L. E. Martin, M. R. Rosner, Protein kinase C ζ mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 66, 6296-6303 (2006).
19. J. M. Stommel, A. C. Kimmelman, H. Ying, R. Nabioullin, A. H. Ponugoti, R. Wiedemeyer, A. H. Stegh, J. E. Bradner, K. L. Ligon, C. Brennan, L. Chin, R. A. DePinho, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
20. H. J. Jun, J. Acquaviva, D. Chi, J. Lessard, H. Zhu, S. Woolfenden, R. T. Bronson, R. Pfannl, F. White, D. E. Housman, L. Iyer, C. A. Whittaker, A. Boskovitz, A. Raval, A. Charest, Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 31, 3039-3050 (2012).
21. M. L. Standaert, G. Bandyopadhyay, Y. Kanoh, M. P. Sajan, R. V. Farese, Insulin and PIP3 activate PKC-ζ by mechanisms that are both dependent and independent of phosphorylation of activation loop (T410) and autophosphorylation (T560) sites. Biochemistry 40, 249-255 (2001).
22. J. A. Le Good, W. H. Ziegler, D. B. Parekh, D. R. Alessi, P. Cohen, P. J. Parker, Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281, 2042-2045 (1998).
23. M. M. Chou, W. Hou, J. Johnson, L. K. Graham, M. H. Lee, C. S. Chen, A. C. Newton, B. S. Schaffhausen, A. Toker, Regulation of protein kinase C ζ by PI 3-kinase and PDK-1. Curr. Biol. 8, 1069-1077 (1998).
24. F. Uberall, K. Hellbert, S. Kampfer, K. Maly, A. Villunger, M. Spitaler, J. Mwanjewe, G. Baier-Bitterlich, G. Baier, H. H. Grunicke, Evidence that atypical protein kinase C-l and atypical protein kinase C-ζ participate in Ras-mediated reorganization of the F-actin cytoskeleton. J. Cell Biol. 144, 413 -425 (1999).
25. M. W. Wooten, M. L. Vandenplas, M. L. Seibenhener, T. Geetha, M. T. Diaz-Meco, Nerve growth factor stimulates multisite tyrosine phosphorylation and activation of the atypical protein kinase C's via a src kinase pathway. Mol. Cell. Biol. 21, 8414-8427 (2001).
26. E. M. Rodriguez, E. E. Dunham, G. S. Martin, Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells. J. Cell. Physiol. 221, 171-182 (2009).
27. M. J. Bissell, W. C. Hines, Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17, 320-329 (2011).
28. L. M. Coussens, Z. Werb, Inflammation and cancer. Nature 420, 860-867 (2002).
29. M. E. Lukashev, Z. Werb, ECM signalling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 8, 437-441 (1998).
30. L. A. Liotta, E. C. Kohn, The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
31. M. J. Bissell, M. A. Labarge, Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell 7, 17-23 (2005).
32. B. Ruffell, N. I. Affara, L. M. Coussens, Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33, 119- 126 (2012).
33. T. A. Wynn, A. Chawla, J. W. Pollard, Macrophage biology in development, homeostasis and disease. Nature 496, 445-455 (2013).
34. F. R. Balkwill, A. Mantovani, Cancer-related inflammation: Common themes and therapeutic opportunities. Semin. Cancer Biol. 22, 33-40 (2012).
35. G. P. Atkinson, S. E. Nozell, E. T. Benveniste, NF-κB and STAT3 signaling in glioma: Targets for future therapies. Expert Rev. Neurother. 10, 575- 586 (2010).
36. M. Karin, NF-κB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 1, a000141 (2009).
37. Y. Ben-Neriah, M. Karin, Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 12, 715- 723 (2011).
38. M. M. Chaturvedi, B. Sung, V. R. Yadav, R. Kannappan, B. B. Aggarwal, NF-κB addiction and its role in cancer: "One size does not fit all". Oncogene 30, 1615-1630 (2011).
39. W. E. Naugler, M. Karin, NF-κB and cancer - Identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26 (2008).
40. T. Laver, S. Nozell, E. N. Benveniste, The NF-κB signaling pathway in GBMs: Implications for apoptotic and inflammatory responses and exploitation for therapy, in CNS Cancer Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches, E. G. Van Meir, Ed. (Humana Press, New York, 2009) pp. 1011-1036.
41. L. M. Staudt, Oncogenic activation of NF-κB. Cold Spring Harb. Perspect. Biol. 2, a000109 (2010).
42. H. Wang, W. Zhang, H. J. Huang, W. S. Liao, G. N. Fuller, Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas. Lab. Invest. 84, 941-951 (2004).
43. M. Bredel, D. M. Scholtens, A. K. Yadav, A. A. Alvarez, J. J. Renfrow, J. P. Chandler, I. L. Yu, M. S. Carro, F. Dai, M. J. Tagge, R. Ferrarese, C. Bredel, H. S. Phillips, P. J. Lukac, P. A. Robe, A. Weyerbrock, H. Vogel, S. Dubner, B. Mobley, X. He, A. C. Scheck, B. I. Sikic, K. D. Aldape, A. Chakravarti, G. R. T. Harsh, NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364, 627-637 (2011).
44. S. I. Grivennikov, M. Karin, Inflammation and oncogenesis: A vicious connection. Curr. Opin. Genet. Dev. 20, 65-71 (2010).
45. A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation. Nature 454, 436-444 (2008).
46. S. Tsuchiya, Y. Kobayashi, Y. Goto, H. Okumura, S. Nakae, T. Konno, K. Tada, Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 42, 1530-1536 (1982).
47. A. Valster, N. L. Tran, M. Nakada, M. E. Berens, A. Y. Chan, M. Symons, Cell migration and invasion assays. Methods 37, 208-215 (2005).
48. A. Mantovani, A. Sica, Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237 (2010).
49. S. I. Grivennikov, M. Karin, Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 70 (Suppl.1), i104-i108 (2011).
50. J. Terzić, S. Grivennikov, E. Karin, M. Karin, Inflammation and colon cancer. Gastroenterology 138, 2101-2114.e5 (2010).
51. M. T. Diaz-Meco, I. Dominguez, L. Sanz, P. Dent, J. Lozano, M. M. Municio, E. Berra, R. T. Hay, T. W. Sturgill, J. Moscat, ζPKC induces phosphorylation and inactivation of IκB-α in vitro. EMBO J. 13, 2842-2848 (1994).
52. A. Duran, M. T. Diaz-Meco, J. Moscat, Essential role of RelA Ser311 phosphorylation by ζPKC in NF-κB transcriptional activation. EMBO J. 22, 3910- 3918 (2003).
53. M. Leitges, L. Sanz, P. Martin, A. Duran, U. Braun, J. F. Garcia, F. Camacho, M. T. Diaz-Meco, P. D. Rennert, J. Moscat, Targeted disruption of the ζPKC gene results in the impairment of the NF-κB pathway. Mol. Cell 8, 771-780 (2001).
54. J. Moscat, M. T. Diaz-Meco, The atypical protein kinase Cs. Functional specificity mediated by specific protein adapters. EMBO Rep. 1, 399-403 (2000).
55. A. do Carmo, J. Balc¸a-Silva, D. Matias, M. C. Lopes, PKC signaling in glioblastoma. Cancer Biol. Ther. 14, 287-294 (2013).
56. J. Moscat, M. T. Diaz-Meco, M. W. Wooten, Of the atypical PKCs, Par-4 and p62: Recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ. 16, 1426-1437 (2009).
57. S. S. Parker, E. K. Mandell, S. M. Hapak, I. Y. Maskaykina, Y. Kusne, J. Y. Kim, J. K. Moy, P. A. St John, J. M. Wilson, K. M. Gothard, T. J. Price, S. Ghosh, Competing molecular interactions of aPKC isoforms regulate neuronal polarity. Proc. Natl. Acad. Sci. U.S.A. 110, 14450-14455 (2013).
58. The Cancer Genome Atlas Research Network; R. McLendon, A. Friedman, D. Bigner, E. G. Van Meir, D. J. Brat, M. Mastrogianakis, J. J. Olson, T. Mikkelsen, N. Lehman, K. Aldape, W. K. Alfred Yung, O. Bogler, S. Vandenberg, M. Berger, M. Prados, D. Muzny, M. Morgan, S. Scherer, A. Sabo, L. Nazareth, L. Lewis, O. Hall, Y. Zhu, Y. Ren, O. Alvi, J. Yao, A. Hawes, S. Jhangiani, G. Fowler, A. San Lucas, C. Kovar, A. Cree, H. Dinh, J. Santibanez, V. Joshi, M. L. Gonzalez-Garay, C. A. Miller, A. Milosavljevic, L. Donehower, D. A. Wheeler, R. A. Gibbs, K. Cibulskis, C. Sougnez, T. Fennell, S. Mahan, J. Wilkinson, L. Ziaugra, R. Onofrio, T. Bloom, R. Nicol, K. Ardlie, J. Baldwin, S. Gabriel, E. S. Lander, L. Ding, R. S. Fulton, M. D. McLellan, J. Wallis, D. E. Larson, X. Shi, R. Abbott, L. Fulton, K. Chen, D. C. Koboldt, M. C. Wendl, R. Meyer, Y. Tang, L. Lin, J. R. Osborne, B. H. Dunford-Shore, T. L. Miner, K. Delehaunty, C. Markovic, G. Swift, W. Courtney, C. Pohl, S. Abbott, A. Hawkins, S. Leong, C. Haipek, H. Schmidt, M. Wiechert, T. Vickery, S. Scott, D. J. Dooling, A. Chinwalla, G. M. Weinstock, E. R. Mardis, R. K. Wilson, G. Getz, W. Winckler, R. G. Verhaak, M. S. Lawrence, M. O'Kelly, J. Robinson, G. Alexe, R. Beroukhim, S. Carter, D. Chiang, J. Gould, S. Gupta, J. Korn, C. Mermel, J. Mesirov, S. Monti, H. Nguyen, M. Parkin, M. Reich, N. Stransky, B. A. Weir, L. Garraway, T. Golub, M. Meyerson, L. Chin, A. Protopopov, J. Zhang, I. Perna, S. Aronson, N. Sathiamoorthy, G. Ren, W. R. Wiedemeyer, H. Kim, S. Won Kong, Y. Xiao, I. S. Kohane, J. Seidman, P. J. Park, R. Kucherlapati, P. W. Laird, L. Cope, J. G. Herman, D. J. Weisenberger, F. Pan, D. Van Den Berg, L. Van Neste, J. Mi Yi, K. E. Schuebel, S. B. Baylin, D. M. Absher, J. Z. Li, A. Southwick, S. Brady, A. Aggarwal, T. Chung, G. Sherlock, J. D. Brooks, R. M. Myers, P. T. Spellman, E. Purdom, L. R. Jakkula, A. V. Lapuk, H. Marr, S. Dorton, Y. Gi Choi, J. Han, A. Ray, V. Wang, S. Durinck, M. Robinson, N. J. Wang, K. Vranizan, V. Peng, E. Van Name, G. V. Fontenay, J. Ngai, J. G. Conboy, B. Parvin, H. S. Feiler, T. P. Speed, J. W. Gray, C. Brennan, N. D. Socci, A. Olshen, B. S. Taylor, A. Lash, N. Schultz, B. Reva, Y. Antipin, A. Stukalov, B. Gross, E. Cerami, W. Qing Wang, L. X. Qin, V. E. Seshan, L. Villafania, M. Cavatore, L. Borsu, A. Viale, W. Gerald, C. Sander, M. Ladanyi, C. M. Perou, D. Neil Hayes, M. D. Topal, K. A. Hoadley, Y. Qi, S. Balu, Y. Shi, J. Wu, R. Penny, M. Bittner, T. Shelton, E. Lenkiewicz, S. Morris, D. Beasley, S. Sanders, A. Kahn, R. Sfeir, J. Chen, D. Nassau, L. Feng, E. Hickey, J. N. Weinstein, A. Barker, D. S. Gerhard, J. Vockley, C. Compton, J. Vaught, P. Fielding, M. L. Ferguson, C. Schaefer, S. Madhavan, K. H. Buetow, F. Collins, P. Good, M. Guyer, B. Ozenberger, J. Peterson, E. Thomson, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
59. T. G. Bivona, H. Hieronymus, J. Parker, K. Chang, M. Taron, R. Rosell, P. Moonsamy, K. Dahlman, V. A. Miller, C. Costa, G. Hannon, C. L. Sawyers, FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526 (2011).
60. B. Badie, J. M. Schartner, Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46, 957-961; discussion 961-952 (2000).
61. N. A. Charles, E. C. Holland, R. Gilbertson, R. Glass, H. Kettenmann, The brain tumor microenvironment. Glia 59, 1169-1180 (2011).
62. W. Roggendorf, S. Strupp, W. Paulus, Distribution and characterization of microglia/ macrophages in human brain tumors. Acta Neuropathol. 92, 288-293 (1996).
63. S. F. Hussain, D. Yang, D. Suki, K. Aldape, E. Grimm, A. B. Heimberger, The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 8, 261-279 (2006).
64. I. F. Parney, J. S. Waldron, A. T. Parsa, Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J. Neurosurg. 110, 572-582 (2009).
65. H. Galarneau, J. Villeneuve, G. Gowing, J. P. Julien, L. Vallières, Increased glioma growth in mice depleted of macrophages. Cancer Res. 67, 8874-8881 (2007).
66. L. Zhang, D. Alizadeh, M. Van Handel, M. Kortylewski, H. Yu, B. Badie, Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 57, 1458-1467 (2009).
67. I. Bettinger, S. Thanos, W. Paulus, Microglia promote glioma migration. Acta Neuropathol. 103, 351-355 (2002).
68. H. Zhai, F. L. Heppner, S. E. Tsirka, Microglia/macrophages promote glioma progression. Glia 59, 472-485 (2011).
69. D. S. Markovic, R. Glass, M. Synowitz, N. Rooijen, H. Kettenmann, Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J. Neuropathol. Exp. Neurol. 64, 754-762 (2005).
70. D. S. Markovic, K. Vinnakota, S. Chirasani, M. Synowitz, H. Raguet, K. Stock, M. Sliwa, S. Lehmann, R. Kälin, N. van Rooijen, K. Holmbeck, F. L. Heppner, J. Kiwit, V. Matyash, S. Lehnardt, B. Kaminska, R. Glass, H. Kettenmann, Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. U.S.A. 106, 12530 -12535 (2009).
71. S. J. Coniglio, E. Eugenin, K. Dobrenis, E. R. Stanley, B. L. West, M. H. Symons, J. E. Segall, Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 18, 519-527 (2012).
72. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher, R. L. Bowman, L. Sevenich, D. F. Quail, O. C. Olson, M. L. Quick, J. T. Huse, V. Teijeiro, M. Setty, C. S. Leslie, Y. Oei, A. Pedraza, J. Zhang, C. W. Brennan, J. C. Sutton, E. C. Holland, D. Daniel, J. A. Joyce, CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013).
73. K. P. Bhat, V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, K. Hummelink, F. Hollingsworth, K. Wani, L. Heathcock, J. D. James, L. D. Goodman, S. Conroy, L. Long, N. Lelic, S. Wang, J. Gumin, D. Raj, Y. Kodama, A. Raghunathan, A. Olar, K. Joshi, C. E. Pelloski, A. Heimberger, S. H. Kim, D. P. Cahill, G. Rao, W. F. Den Dunnen, H. W. Boddeke, H. S. Phillips, I. Nakano, F. F. Lang, H. Colman, E. P. Sulman, K. Aldape, Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24, 331-346 (2013).
74. S. L. Shiao, A. P. Ganesan, H. S. Rugo, L. M. Coussens, Immune microenvironments in solid tumors: New targets for therapy. Genes Dev. 25, 2559-2572 (2011).
75. L. M. Coussens, L. Zitvogel, A. K. Palucka, Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science 339, 286- 291 (2013).
76. G. Tiscornia, O. Singer, I. M. Verma, Production and purification of lentiviral vectors. Nat. Protoc. 1, 241-245 (2006).
77. S. Ghosh, V. Tergaonkar, C. V. Rothlin, R. G. Correa, V. Bottero, P. Bist, I. M. Verma, T. Hunter, Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-κB activation and cell survival. Cancer Cell 10, 215-226 (2006).
78. F. Pistollato, L. Persano, A. D. Puppa, E. Rampazzo, G. Basso, Isolation and expansion of regionally defined human glioblastoma cells in vitro. Curr. Protoc. Stem Cell Biol. Chap. 3, Unit 3.4 (2011).